Caris Life Sciences vs Corvel
Corvel is the larger business, with $959m of revenue in fiscal 2026 against $812m for Caris Life Sciences (1.2 times as much). Caris Life Sciences grew faster (97.0% against 7.0%). Corvel kept more of each dollar of sales as profit: a net margin of 11.5% against -8.4%. Corvel carries less debt relative to equity (0.0% against 65.6%).
| Latest fiscal year | Caris Life SciencesCAI, 2025 | CorvelCRVL, 2026 |
|---|---|---|
| Revenue | $812m | $959m |
| Revenue growth | 97.0% | 7.0% |
| Net income | −$68.1m | $110m |
| Operating margin | 5.6% | — |
| Net margin | -8.4% | 11.5% |
| Return on equity | — | 30.8% |
| Free cash flow | $66.9m | $110m |
| Cash | $796m | $233m |
| Total debt | $379m | $0 |
| Debt to equity | 65.6% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $113,000 | $56.2m |
| Employees | 1,846 | 5,239 |
| Market value | $9.33bn | $4.20bn |
| Price vs our value range | — | — |
| Moat score | — | 68 (Moderate) |
| Insider trades, 12 months | 4 buys, 7 sales | 0 buys, 26 sales |